ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY
Lodovico Terzi di Bergamo(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Silke Gillessen(Institute of Oncology Research), Francesco Passamonti(University of Milan), Claudio Martines(International Centre for Genetic Engineering and Biotechnology), Georg Stüssi(Institute of Oncology Research), Antonella Zucchetto(Centro di Riferimento Oncologico), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Dimitar G. Efremov(Macedonian Academy of Sciences and Arts), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Hossein Khiabanian(Rutgers, The State University of New Jersey), Tamara Bittolo(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Francesco Autore(Agostino Gemelli University Polyclinic), Luca Laurenti(Sapienza University of Rome), Lydia Scarfò(IRCCS Ospedale San Raffaele), Erika Tissino(Centro di Riferimento Oncologico), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Wei Wu(Institute of Oncology Research), Franco Cavalli(Institute of Social and Preventive Medicine), Katia Pini(Institute of Oncology Research), Silvia Rasi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), B. Gerber(University of Zurich), Jui Wan Loh(Southwestern Medical Center), Michele Merli(University of Insubria), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Gabriela Forestieri(Institute of Oncology Research), Amartya Singh(Rutgers, The State University of New Jersey), Ricardo Koch(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Martin Faderl(Institute of Oncology Research), Paolo Ghia(Vita-Salute San Raffaele University), Emanuele Zucca(Università della Svizzera italiana), Michael Gregor(University of Lucerne), Alessio Bruscaggin(Institute of Oncology Research), Valeria Spina(Ente Ospedaliero Cantonale), Jakob Passweg(University Hospital of Basel)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k